HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow Inc has demonstrated significant growth in its pharmaceutical sales, with total revenue increasing from $88.6 million in 2022 to $130.2 million in 2023, representing a 47% year-over-year increase. The company's new product VEVYE, launched in January 2024, surpassed management's expectations with a 55% increase in prescription volume in the third quarter of 2024, generating $5.2 million in sales. Additionally, IHEEZO has experienced remarkable growth, with unit sales soaring from 6,471 in the third quarter of 2023 to 34,468 in the third quarter of 2024, resulting in $12.9 million in revenue for the latest quarter.
Bears say
Harrow Inc. is facing a challenging financial landscape characterized by a recent decline in operating income and adjusted EBITDA despite a temporary recovery in the second and third quarters of 2024. The company's smaller size and limited financial resources hinder its ability to capture substantial market share, compounded by regulatory changes and biotechnology advancements that could render its products uncompetitive. Additionally, risks such as difficulties in new product integration, maintaining healthy cash flows, serviceability of $216 million in outstanding debt, and potential regulatory non-compliance pose significant threats to Harrow's growth and profitability outlook.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares